tadalafil has been researched along with trifluoperazine in 1 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (trifluoperazine) | Trials (trifluoperazine) | Recent Studies (post-2010) (trifluoperazine) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 3,696 | 157 | 198 |
| Protein | Taxonomy | tadalafil (IC50) | trifluoperazine (IC50) |
|---|---|---|---|
| Genome polyprotein | 0.7 | ||
| Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens (human) | 8 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Lysozyme C-1 | Rattus norvegicus (Norway rat) | 9 | |
| Beta-glucuronidase | Rattus norvegicus (Norway rat) | 7.8 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 6.75 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 6.226 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | 1.4 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.016 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 6.226 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 6.226 | |
| WD repeat-containing protein 48 | Homo sapiens (human) | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for tadalafil and trifluoperazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |